Study of CLL Treatment After Stopping BTK Inhibitor Drugs
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study follows patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)—blood cancers—who have been taking a type of targeted drug called a BTK inhibitor for at least 2 years. Researchers want to understand what happens to these patients' cancer and health after they stop taking this medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of CLL (chronic lymphocytic leukemia) or SLL (small lymphocytic lymphoma)
- You are currently taking a covalent BTK inhibitor drug (a targeted cancer medication) and have been taking it for at least 2 years
- Your cancer is stable—you do not have signs that it is growing or getting worse right now
- You are at least 18 years old
- You are able to participate in study visits and procedures, as judged by your doctor
- You are willing to sign consent forms allowing researchers to access your medical information
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well blood pressure is managed and whether heart problems can be prevented in people with certain blood cancers who are taking a type of targeted therapy called a BTKi. It aims to help you stay healthier during treatment.
This study looks at CLL patients who are taking or may take a BTK degrader (a newer type of targeted therapy) to find out what factors influence how well the treatment works. It aims to help doctors understand who benefits most from this approach.
This trial studies whether taking ibrutinib in a less continuous (“intermittent”) schedule can keep your chronic lymphocytic leukemia (CLL) under control. It’s for people who have already received ibrutinib for at least 6 months and had a good early response, aiming to reduce treatment intensity while tracking safety and cancer control.
This trial tests whether adding venetoclax to your current BTK inhibitor (like ibrutinib, acalabrutinib, or zanubrutinib) works better than taking the BTK inhibitor alone. It's for veterans with CLL or SLL who have been on a BTK inhibitor for at least six months and have not had their disease get worse on that therapy.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This study tests a new drug called NX-5948 against an existing drug (pirtobrutinib) for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to a previous BTK inhibitor treatment. The goal is to see if NX-5948 works better or is safer for this hard-to-treat situation.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.